Summit Therapeutics is expected to report results around 27 October, an estimate drawn from its filing history rather than a confirmed date. The clinical-stage biopharmaceutical company’s trailing-twelve-month cash flow figures, drawn from its 10-Q filings through the second quarter of fiscal 2026, set a clear bar for what the next report needs to show.
Three questions this report will answer
Is the cash burn still accelerating? Operating cash flow fell 121.6% year-on-year on a trailing-twelve-month basis, to −$458.4 million. Free cash flow moved almost in step, falling 121.7% to −$459.8 million. A company already running at this scale of annual cash outflow has limited room for the trend to simply continue at the same rate without raising the question of how the next twelve months are funded. The report will show whether the rate of decline is holding steady, steepening further, or beginning to flatten.
Is capital spending scaling with the pipeline? Capital expenditure grew 181.2% over the trailing year to $1.4 million. The absolute figure is small for a company of this size, which is typical for a clinical-stage drug developer with no manufacturing base of its own, but the rate of growth is notable. If spending on property and equipment keeps compounding at anything close to this pace, it points to a company building out infrastructure ahead of a commercial-stage transition. If it levels off, that infrastructure build may already be largely complete.
Is the share count still growing at the same pace? Diluted shares outstanding grew 4.0% year-on-year on a trailing basis. For a company running a cash loss of this size, equity issuance is one of the few funding levers available alongside partnership payments or debt. The next filing will show whether that 4.0% pace of dilution is continuing, accelerating, or slowing.
What would confirm or break each trend
A continuation of the current trajectory, operating cash flow and free cash flow both still falling at a rate near 121% year-on-year, would confirm that the company remains in a heavy investment phase with spending needs still rising.
Dilution running well above 4.0% would point to a funding need outpacing the previous year’s pace. Dilution holding near or below that level, alongside stable or improving cash flow figures, would suggest the company is managing its capital needs within a more predictable band.
| Metric (TTM) | Value | YoY change |
|---|---|---|
| Operating cash flow | −$458.4 million | −121.6% |
| Free cash flow | −$459.8 million | −121.7% |
| Net income | −$856.1 million | −14.7% |
| Capital expenditure | $1.4 million | +181.2% |
| Diluted shares outstanding | — | +4.0% |
What it means for value
A clinical-stage company’s cash flow trajectory feeds directly into the free cash flow assumptions used in a discounted cash flow model. The scale of this period’s decline, operating cash flow falling 121.6% and free cash flow falling 121.7% year-on-year, represents exactly the kind of input that moves a model’s forecast cash flows when it persists or reverses. A continuation of the current burn rate implies funding needs stretching further into the future; a narrowing implies the opposite, with less capital required to reach any eventual commercial stage. The 4.0% rise in diluted shares outstanding is a separate input: it affects the per-share allocation of whatever cash flows the model projects, independent of the cash flow trend itself.
These are model values under stated assumptions, not a comparison with the share price.
The other reading
The widening cash outflow and rising share count could also reflect a company in the capital-intensive run-up to important trial data or regulatory filings, spending that a licensing payment, partnership milestone or commercial launch could later offset. Nothing in the filing data used here identifies the specific driver of the quarter’s spending; a report’s explanation of near-term catalysts, where one exists, would need to be checked against the company’s own disclosure rather than inferred from the cash flow figures alone. The scale of the trailing twelve-month loss, down to −$856.1 million, is large enough that the next filing’s commentary on trial progress and funding plans will likely carry more information than the headline cash flow number by itself.
No consensus analyst estimate or company guidance figure for the coming report appears in the data used for this preview, so none is cited here.
